- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Channel Therapeutics advances non-opioid pain treatment | 1 | Investing.com | ||
| CHANNEL THERAPEUTICS CORPORATION Aktie jetzt für 0€ handeln | |||||
| Fr | Channel Therapeutics erzielt Fortschritte bei nicht-opioidhaltiger Schmerztherapie | 1 | Investing.com Deutsch | ||
| Fr | Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine | 87 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen | |
| 18.12. | Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model | 59 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen | |
| 21.11. | Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates | 126 | GlobeNewswire (Europe) | "Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts... ► Artikel lesen | |
| 19.11. | Channel Therapeutics finalizes corporate restructuring | - | Investing.com | ||
| 18.11. | Channel Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Chromocell Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | Chromocell announces amendment to stock repurchase plan | 1 | Seeking Alpha | ||
| 24.10. | Chromocell boosts stock buyback plan to $750,000 | 1 | Investing.com | ||
| 24.10. | Chromocell Therapeutics Announces Amendment to Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
| 24.10. | Chromocell Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Chromocell therapeutics CEO buys $5,044 in company stock | 1 | Investing.com | ||
| 16.09. | Chromocell therapeutics director buys $9.8k in stock | 1 | Investing.com | ||
| 12.09. | Chromocell Therapeutics CEO buys shares worth over $10,000 | 1 | Investing.com | ||
| 13.08. | Chromocell Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Chromocell Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.08. | Chromocell announces stock repurchase plan | 1 | Seeking Alpha | ||
| 07.08. | Chromocell Therapeutics Announces Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
| 29.07. | Chromocell Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Das Unternehmen CHANNEL THERAPEUTICS CORPORATION kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,631 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHANNEL THERAPEUTICS CORPORATION finden Sie auf Wallstreet Online.
